hotspot -WSS

hotspot

author：entertainment 2025-10-01 12:35:46 - browse：752

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Life sciences investors close nearly $6 billion in new funds

focus

WSS

Inari Medical to buy amputation prevention company LimFlow

In key trial, Verve's treatment lowers cholesterol levels in patients

Poor hospice wound care hurts patients and families

Kidney transplant patients stopped immunosuppressants in trial

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

PBM reforms clear House panel

focus

hotspot

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Astellas still sees hope in its gene therapy after four deaths

New air purifier tech could be key to improving indoor air quality

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

At least 13 dead in Texas as scorching temps continue

Prime Medicine says its gene editing passes test in monkeys

Walensky prepares to leave CDC — and Congress — behind

DeepMind touts AlphaFold's new skills as protein folding AI models face off

focus

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Life sciences investors close nearly $6 billion in new funds

After Sarepta trial failure, Duchenne families brace for more debate

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Medicare must police algorithms in Medicare Advantage, Dems say

focus

hotspot

entertainment

hotspot